This company listing is no longer active
OKYO Stock Overview
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
OKYO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.91 |
| 52 Week High | UK£3.90 |
| 52 Week Low | UK£0.88 |
| Beta | -0.062 |
| 1 Month Change | -9.68% |
| 3 Month Change | -65.69% |
| 1 Year Change | -63.64% |
| 3 Year Change | -45.10% |
| 5 Year Change | n/a |
| Change since IPO | -98.13% |
Recent News & Updates
Recent updates
Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?
Nov 26
Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?
Jan 27Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation
Sep 22We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth
Mar 17We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow
Dec 02Shareholder Returns
| OKYO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -31.7% | -2.3% | -0.7% |
| 1Y | -63.6% | -29.4% | -1.8% |
Return vs Industry: OKYO underperformed the UK Biotechs industry which returned -16.5% over the past year.
Return vs Market: OKYO underperformed the UK Market which returned -2.2% over the past year.
Price Volatility
| OKYO volatility | |
|---|---|
| OKYO Average Weekly Movement | 18.1% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: OKYO's share price has been volatile over the past 3 months.
Volatility Over Time: OKYO's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 7 | Gary Jacob | www.okyopharma.com |
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.
OKYO Pharma Limited Fundamentals Summary
| OKYO fundamental statistics | |
|---|---|
| Market cap | UK£23.22m |
| Earnings (TTM) | -UK£6.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs OKYO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OKYO income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£4.39m |
| Gross Profit | -UK£4.39m |
| Other Expenses | UK£2.31m |
| Earnings | -UK£6.70m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OKYO perform over the long term?
See historical performance and comparison